Research and development daily: three famous antihypertensive drugs have commented on the market of Tiandi Hengyi equal share food of nearly 1 billion yuan

Three big varieties of antihypertensive drugs have been evaluated! Two clinical trials of Gilead's most potential anti-inflammatory drug filgotinib failed! 78% objective remission rate: the clinical results of new therapy for intractable brain tumor in children are positive We focus on the latest development of pharmaceutical research and development, and provide timely and accurate information reference for R & D personnel On October 28, Tiandi Hengyi Pharmaceutical Co., Ltd received the approval document of supplementary application for chemicals candesartan ester tablets approved and issued by the State Food and drug administration, which passed the conformity evaluation of generic drugs Candesartan dipivoxil is an angiotension II receptor antagonist According to the data of minenet, in 2018, the sales volume of candesartan dipivoxil at the terminal of public medical institutions in China was nearly 1 billion yuan In 2017, Gilead launched two studies (nct03134222 and nct03100942) targeting women with moderate to severe lupus erythematosus and Sjogren's syndrome, with results planned for the second half of 2019 Recently, John sundy, senior vice president of Geely's third quarter performance conference call, revealed that despite the "positive evidence" seen in previous studies, the final two trials did not reach the main end point Recently, y-mabs therapeutics announced at the annual meeting of the international children's cancer association that its humanized monoclonal antibody, naxitamab, targeting gD2 antigen, combined with GM-CSF, has obtained positive efficacy and safety data in clinical trials for children with neuroblastoma and osteosarcoma.